Rezolute, Inc. (RZLT) stock
RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
$4.25+0.24 (+5.85%)
Close on Nov 18, 2026Market cap $411.07MP/E –Yield –
Rezolute operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rezolute's operating income for the twelve months ending Sep 30, 2026 was -$82.53M. For fiscal 2026 it was -$82.97M. The highest annual figure on record is -$392.98K in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$82.97M | – |
| FY2025 | Jun 30, 2025 | -$79.89M | – |
| FY2024 | Jun 30, 2024 | -$70.42M | – |
| FY2023 | Jun 30, 2023 | -$55.99M | – |
| FY2022 | Jun 30, 2022 | -$41.84M | – |
| FY2021 | Jun 30, 2021 | -$22.89M | – |
| FY2020 | Jun 30, 2020 | -$20.52M | – |
| FY2019 | Jun 30, 2019 | -$25.94M | – |
| FY2018 | Jun 30, 2018 | -$28.73M | – |
| FY2017 | Jun 30, 2017 | -$20.32M | – |
| FY2016 | Jun 30, 2016 | -$14.95M | – |
| FY2015 | Jun 30, 2015 | -$10.70M | – |
| FY2014 | Jun 30, 2014 | -$5.18M | – |
| FY2011 | Dec 31, 2011 | -$392.98K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$19.39M | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$21.56M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$17.37M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$24.22M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$19.82M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$25.85M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$20.02M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$17.08M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$16.94M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$23.10M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$16.21M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$15.19M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$15.91M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$14.24M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$17.14M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$14.39M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$10.22M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$11.30M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$10.75M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$12.15M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$7.64M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$6.64M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$5.48M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$7.15M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$3.62M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$3.55M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$5.07M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$6.72M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$5.18M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$11.31M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$4.95M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$5.75M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$6.72M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$6.22M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$5.39M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$4.89M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$3.82M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$3.87M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$3.72M | – |
See a number that looks wrong?